Letairis vs Opsumit
Side-by-side cost comparison based on Medicare Part D data
Letairis
Ambrisentan
Manufactured by Gilead
Opsumit
Macitentan
Manufactured by Janssen
Letairis costs 18% less per claim than Opsumit ($8,338.00 vs $10,186.00). A generic version of Letairis is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Letairis | Opsumit |
|---|---|---|
| Avg Cost Per Claim | $8,338.00 | $10,186.00 |
| Total Medicare Spending | $567.0M | $876.0M |
| Total Beneficiaries | 6,800 | 8,400 |
| Total Claims | 68,000 | 86,000 |
| Annual Cost/Patient | $83,382.00 | $104,286.00 |
| Year-over-Year Change | -4.8% | +4.6% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Gilead | Janssen |
| Condition | Pulmonary Hypertension | Pulmonary Hypertension |
| Generic Name | Ambrisentan | Macitentan |
Letairis vs Opsumit: What the Data Shows
Letairis (Ambrisentan) and Opsumit (Macitentan) are both used to treat pulmonary hypertension. Based on Medicare Part D data, Letairis costs $8,338.00 per claim, which is 18% less than Opsumit at $10,186.00 per claim.
Medicare spent $567.0M on Letairis and $876.0M on Opsumit. In terms of patient reach, Opsumit serves more beneficiaries (8,400 vs 6,800).
Year-over-year spending changed -4.8% for Letairis and +4.6% for Opsumit.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Letairis is cheaper at $8,338.00 per claim, compared to $10,186.00 for Opsumit. That makes Letairis about 18% less expensive per claim based on Medicare Part D data.
Yes, both Letairis and Opsumit are used to treat pulmonary hypertension. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Ambrisentan and generic Macitentan can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Letairis covering 6,800 beneficiaries, and $876.0M on Opsumit covering 8,400 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.